中文名稱:溴芬酸鈉水合物 | 英文名稱:Bromfenac sodium hydrate |
CAS:120638-55-3 | 品牌: 瑞威爾 |
產(chǎn)地: 江西 | 保存條件: 常溫密封儲存 |
純度規(guī)格: ≥98% | 產(chǎn)品類別: API&醫(yī)藥中間體 |
品牌: Revere | CAS編號: 120638-55-3 |
EINECS編號: 695-342-6 | 別名: 溴芬酸鈉 |
分子式: C15H11BrNNaO3 | 含量純度: ≥98% |
產(chǎn)地/廠商: 江西瑞威爾生物 | 英文名稱: Bromfenac sodium hydrate |
性狀: 白色粉沫結(jié)晶 | 儲藏: 室內(nèi)常溫密封儲存 |
單雜: ≤0.1% | 質(zhì)量標(biāo)準(zhǔn): 企業(yè)內(nèi)控標(biāo)準(zhǔn) |
中文名 | 溴芬酸鈉 |
英文名 | Bromfenac sodium |
別名 | 溴芬酸鈉 溴酚酸鈉 溴芬那酸鈉 溴芬酸鈉水合物 溴芬那酸鈉水合物 溴芬酸鈉120638-55-3 (2-氨基-3-(4-溴苯甲酰)苯基)乙酸鈉 [2-氨基-3-(4-溴苯甲酰基)苯基]乙酸鈉 (2-氨基-3-(4-溴苯甲酰)苯基)乙酸鈉水合物 |
英文別名 | Duract Unii-8ecv571Y37 Bromfenac sodium Bromfenac ophthalmic Bromfenac ophthalmic solution Bromfenac Sodium Sesquihydrate Bromfenac monosodium salt sesquihydrate [2-amino-3-(4-bromobenzoyl)phenyl]acetic acid Sodium (2-amino-3-(4-bromobenzoyl)phenyl)acetate Sodium [2-amino-3-(4-bromobenzoyl)phenyl]acetate 2-Amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt Sodium 2-amino-3-(4-bromobenzoyl) phenylacetate sesquihydrate sodium {2-amino-3-[(4-bromophenyl)carbonyl]phenyl}acetate hydrate |
CAS | 91714-93-1 120638-55-3 |
EINECS | 695-342-6 |
化學(xué)式 | C15H11BrNNaO3 |
分子量 | 356.15 |
InChI | InChI=1/C15H12BrNO3.Na.H2O/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19;;/h1-7H,8,17H2,(H,18,19);;1H2/q;+1;/p-1 |
熔點 | 268-270°C (dec.) |
沸點 | 562.2°C at 760 mmHg |
閃點 | 293.8°C |
蒸汽壓 | 1.77E-13mmHg at 25°C |
存儲條件 | Refrigerator |
體外研究 | Bromfenac (90 μg/mL; 48 h) inhibits TGF-b1-induced extracellular matrix (ECM) synthesis and myo?broblast activation in HConFs and HPFs. Bromfenac (30-90 μg/mL; 48 h) decreases the protein and mRNA expression levels of FN, COL3, a-SMA, and survivin in a dose-dependent manner in HConFs and HPFs. Bromfenac (30-90 μg/mL; 48 h) declines the phosphorylated protein levels of AKT, ERK1/2, and GSK-3b-S9 with dosage in HPFs and HConFs. |
體內(nèi)研究 | Bromfenac (0.0032-3.16%; 100 or 200 μL; rubbed onto the backs) produces significant anti-inflammatory activity at concentrations as low as 0.1% (4 h pretreatment time) or 0.32% (18h pretreatment time) in rats. Bromfenac (0.032-3.16%; 100 μL; rubbed onto the paws) produces dose-related anti-inflammatory activity in rats. Bromfenac (0.032-1.0%; 50 μL) is 26 times more potent than indomethacin in blocking the erythema when applied directly onto the skin area exposed to UV light in guinea pigs. Bromfenac (0.0032-0.1%; 50μL; rubbed onto the uninjected paw for 4 h per day and 5 days per week) produces a dose and time dependent reduction in the paw volume of both hind limbs in rats. Bromfenac (0.32%; 50μL; rubbed onto the abdomen) produces significant blockade of abdominal constriction to ACh challenge in mice. Animal Model: Male Sprague-Dawley rats (150-250 g) are injected carrageenan Dosage: 0.0032, 0.01, 0.032, 0.1, 0.32, 1.0, 3.16% (100 or 200 μL) Administration: Rubbed onto the backs before 1-72 h of injected carrageenan Result: Produced significant anti-inflammatory activity when applied 1, 2, and 4 h prior to carrageenan challenge at 0.32%. Applied 1 or 4 h prior to carrageenan challenge was active, but not when applied 24 h (or longer) prior to challenge at 0.2%. |
成立日期 | 2021-02-01 (5年) | 注冊資本 | 200萬 |
員工人數(shù) | 1-10人 | 年營業(yè)額 | ¥ 100萬以內(nèi) |
主營行業(yè) | 化學(xué)農(nóng)藥原藥,中間體,化學(xué)試劑,醫(yī)藥原料,日用化工 | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
¥200 |
VIP9年
|
湖北鴻鑫瑞宇精細(xì)化工有限公司
|
2025-04-24 | |
詢價 |
VIP1年
|
銘龍(咸寧)醫(yī)藥有限公司
|
2025-04-24 | |
詢價 |
VIP3年
|
湖北魏氏化學(xué)試劑股份有限公司
|
2025-04-24 | |
詢價 |
VIP9年
|
濟南尚圣化工有限公司
|
2025-04-24 | |
¥14 |
VIP3年
|
廣州旺晟生物科技有限公司
|
2025-04-23 | |
¥50 |
VIP7年
|
湖北鴻鑫瑞宇精細(xì)化工有限公司
|
2025-04-23 | |
詢價 |
山東博創(chuàng)醫(yī)藥技術(shù)有限公司
|
2025-04-21 | ||
詢價 |
VIP2年
|
杭州柯萊生物醫(yī)藥科技有限公司
|
2025-04-19 | |
詢價 |
VIP1年
|
廣州佳途科技股份有限公司
|
2025-04-14 | |
詢價 |
武漢貝樂葉生物醫(yī)藥科技有限公司
|
2025-03-30 |